Article in Transfusion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 4 institutions in 2 countries.
Genghis H LopezResearch and Development, Clinical Services and Research, Australian Red Cross Lifeblood, Kelvin Grove, Queensland, Australia.ORCID 0000-0001-8568-0604
Morakot EmthipRed Cell Reference Laboratory, National Blood Centre, Thai Red Cross Society, Bangkok, Thailand.
Ploymanee SuwanwootichaiRed Cell Reference Laboratory, National Blood Centre, Thai Red Cross Society, Bangkok, Thailand.
Glenda M MillardResearch and Development, Clinical Services and Research, Australian Red Cross Lifeblood, Kelvin Grove, Queensland, Australia.ORCID 0000-0002-3809-9662
Brett WilsonRed Cell Reference Laboratory, Clinical Services and Research, Australian Red Cross Lifeblood, Kelvin Grove, Queensland, Australia.
Sunisa OnpunsTransfusion Medicine Unit, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Kanchana LaemsriTransfusion Medicine Unit, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Pimol ChiewsilpRed Cell Reference Laboratory, National Blood Centre, Thai Red Cross Society, Bangkok, Thailand.
Robert L FlowerResearch and Development, Clinical Services and Research, Australian Red Cross Lifeblood, Kelvin Grove, Queensland, Australia.
Catherine A HylandResearch and Development, Clinical Services and Research, Australian Red Cross Lifeblood, Kelvin Grove, Queensland, Australia.ORCID 0000-0002-4124-6168
Yew-Wah LiewRed Cell Reference Laboratory, Clinical Services and Research, Australian Red Cross Lifeblood, Kelvin Grove, Queensland, Australia.
Thai Red Cross Society · THAustralian Red Cross Lifeblood · AUQueensland University of Technology · AUUniversity of the Sunshine Coast · AU
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundLow-prevalence antigen s MATERIALS AND
methodsThree family members and four blood donors were investigated in the study. Massively Parallel Sequencing (MPS) was used for genotyping. Standard hemagglutination techniques were used in titration studies, phenotyping, and enzyme/chemical studies. Anti-s, anti-Mi
resultsThe mother was GYP*Mur/Mur. The father and the four donors were GYPB*s/s DISCUSSION: This is the first report of HDFN due to anti-s
Indexed as
Erythroblastosis, FetalMNSs Blood-Group SystemBlood DonorsFemaleFetusGlycophorinsHumansInfant, NewbornMothersPeptide HydrolasesPhenotypePregnancyPrevalenceThailandGlycophorinsGYPB protein, humanMNSs Blood-Group SystemPeptide Hydrolasesanti-sDhaemolytic disease of the fetus and newbornMNS blood group systemprevalence of sD in Thai blood donorssD antigen
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Hemolytic disease of the fetus and newborn caused by anti-s · full record | OpenQuestion